Latest Breaking News On - Bovenau - Page 1 : comparemela.com
Feuer auf Getreidefeld: 60 Feuerwehrleute im Einsatz
volksstimme.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from volksstimme.de Daily Mail and Mail on Sunday newspapers.
Hamburg & Schleswig-Holstein: Feuer auf Getreidefeld: 60 Feuerwehrleute im Einsatz
n-tv.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from n-tv.de Daily Mail and Mail on Sunday newspapers.
Bovenauer Biotech-Firma Richter-Helm Biologics verdreifacht Kapazitäten
kn-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kn-online.de Daily Mail and Mail on Sunday newspapers.
Published: May 12, 2021 By Alex Keown
Shanghai continues to be an area of focus for many pharmaceutical companies seeking a toehold in China. Companies like AstraZeneca, Novartis and others have opened offices in Shanghai. Two months ago, Germany’s Vetter, a contract development and manufacturing organization, opened offices there, and now, ITM AG, another Germany-based company is following suit. ITM AG established a subsidiary in Shanghai to accelerate introduction of its precision oncology portfolio in China.
The subsidiary will expand ITM’s growing operations in China, which is a key emerging market for novel radiomolecular precision oncology. The ITM Shanghai team will focus on expanding and accelerating access of targeted therapeutic and diagnostic radiopharmaceuticals for Chinese patients.
German CDMO Richter-Helm Triples cGMP Production Capacity to Accommodate Global Market Demand
HAMBURG, Germany, May 06, 2021 / B3C newswire / Richter-Helm BioLogics GmbH & Co. KG, a leading Germany-based, cGMP compliant biopharmaceutical Contract Development and Manufacturing Organization (CDMO) announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.
“The market for pharmaceutical biotechnology has been continuously growing and further growth is expected. In order to accommodate demand for high value biopharmaceutical products, Richter-Helm recently started expansion of its microbial manufacturing capacity and continues to push its overall growth strategy.”